Metastasis ability, genomic profile, subtype characteristic and curative efficacy of multiple pulmonary hematogenous metastases in lung cancer

Liuer He; Xin Nie; Jiayi Gao; Yue Yuan; Xue Wang; Xu Li; Fengzhu Guo; Min Tang; Ping Zhang; Lin Li

doi:10.1002/ctm2.1639

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (3) : e1639 DOI: 10.1002/ctm2.1639

LETTER TO THE JOURNAL

Metastasis ability, genomic profile, subtype characteristic and curative efficacy of multiple pulmonary hematogenous metastases in lung cancer

Author information +

History +

PDF

Cite this article

Download citation ▾

Liuer He, Xin Nie, Jiayi Gao, Yue Yuan, Xue Wang, Xu Li, Fengzhu Guo, Min Tang, Ping Zhang, Lin Li. Metastasis ability, genomic profile, subtype characteristic and curative efficacy of multiple pulmonary hematogenous metastases in lung cancer. Clinical and Translational Medicine, 2024, 14(3): e1639 DOI:10.1002/ctm2.1639

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Jubb AM, Pham TQ, Hanby AM, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol. 2004;57(5):504-512.

[2]	Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871-882.

[3]	Hu C, Zhao L, Liu W, et al. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. J Immunother Cancer. 2021;9(12):e003773.

[4]	Perng PS, Hsu HP, Lee PH, Huang CC, Lin CC, Lee JS. Correlation of EGFR mutation subtypes and survival in surgically treated brain metastasis from non-small-cell lung cancer. Asian J Surg. 2023;46(1):269-276.

[5]	Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354-366.

[6]	Yamaguchi H, et al., A Phase II study of Osimertinib for Radiotherapy-Naive central nervous system metastasis from NSCLC: results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L). J Thorac Oncol. 2021;16(12):2121-2132.

[7]

Hou X, Zhou C, Wu G, et al. Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous NSCLC with brain metastases (CAP-BRAIN): a multicenter, open-label, single-arm, phase 2 study. J Thorac Oncol. 2023;18(6):769-779.

[8]	Nogami N, Barlesi F, Socinski MA, et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol. 2022;17(2):309-323.

[9]

Varlotto JM, Wang Y, Sun Z, Wakelee HA, Ramalingam S, Schiller J. Bevacizumab's association with a decreased risk of brain metastases in ECOG-ACRIN E1505, a phase 3 randomized trial of adjuvant chemotherapy with or without bevacizumab in surgically resected NSCLC. JTO Clin Res Rep. 2022;3(3):100274.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.